AstraZeneca PLC AZN
As ofNov 19, 2026, 10:09 AM EST
- YTD
- -4.22%
- 1 year
- -1.05%
Discussion (253)
Vaccine and profits not here
AZN !
Wait. The sun ☀️ will come!
Big news in Australia about AZN. Back it and it will back you.
https://www.bnnbloomberg.ca/vaccine-may-halt-severe-cases-new-japan-measures-virus-update-1.1526820
Astra Shot Data Hint at Halting Severe Covid (5:55 p.m. NY)
The leader of the U.S. government’s coronavirus vaccine program said AstraZeneca Plc found that 16 participants who received a placebo in its clinical trial contracted severe Covid-19, a sign that the shot could block the worst cases of disease.
The British drugmaker and its partner, the University of Oxford, said earlier Monday that none of the trial participants who received the vaccine had become severely ill, and that none of the patients in that group were hospitalized.
“That’s very important,” said Moncef Slaoui, chief scientific adviser to Operation Warp Speed, in an interview with Bloomberg News. “It’s exciting.”
https://www.inverse.com/mind-body/oxford-vaccine-trial-results-tease-a-huge-benefit
THE OXFORD VACCINE REVEALS 1 'PROVOCATIVE' FINDING OTHER TRIALS ARE MISSING
"The light is getting brighter at the end of the tunnel."
Iryna Veklich/Getty Images
EMMA BETUEL
3 HOURS AGO
NOVEMBER HAS BEEN A HUGE MONTH FOR VACCINE NEWS, and promising vaccine results continue to roll in. On Monday, the University of Oxford and the drugmaker AstraZeneca released exciting interim results from a Phase 3 trial of another coronavirus vaccine candidate, indicating two different levels of efficacy depending on the dosage.
The vaccine was 62 percent effective in preventing disease participants given two standard doses of the vaccine, one month apart. Meanwhile, the vaccine was 90 percent effective in participants who received a half dose and then a full dose one month later. The results were based on 131 Covid-19 cases
The Oxford vaccine news makes for a fortunate pattern: For the past three weeks, Mondays have meant vaccine announcements. This announcement follows those made by the drugmakers Pfizer and Moderna.
The 90 percent figure, achieved with the half dose followed by a full dose, would put the Oxford vaccine in league with Moderna’s vaccine candidate (94.5 percent effective) and Pfizer’s vaccine (95 percent effective).
But unlike the other leading vaccine candidates, the Oxford vaccine may prove to be advantageous in three unique ways:
Early data suggests it offers a glimmer of hope for controlling the spread of the virus.
It may be cheaper: about $2.50 per dose compared to Pfizer’s $20 and Moderna's $15 to $25 per dose.
It will probably prove easier to transport, though the dosage scheme could pose problems later on.
It's the potential for controlling the spread of the virus that makes the Oxford vaccine especially different, based on these early results. Other vaccine trials have not reported any data on how the vaccines perform in the face of asymptomatic cases. The Oxford vaccine press release suggests there were fewer asymptomatic infections among those who got the vaccine.
Well
Messenger RNA.... PFE& MRNA using a brand new method.
AZN using a well known method.
Guys.... patient will be doing well with us.
I’m not the smart guy in the world but I’m sure that AZN have better vaccine I think that more and more contracts with AZN and governments all over the world will be made in the next week
Now it a foggy morning.Here come the ☀️!
A normal flu vaccine is just over 50% effective. 70% sounds good to me. Go AZN
Guys.
We are not in Olomouc games. We talking science ?.
AZN give much more details to public
OMG. It is SOOO clear
In one of the 2 procedures they achieve 90 % of efficacy.
So. They will go to FDA with this procedure!
70% is the average between the 2 BUT WHO CARE about it!!!
We talking about 90% efficacy. It’s clear to me that AZN has the best one so far
Now it’s a foggy ? picture
Wait a day or 3 and you will see the BIG BANG !!
When the fog will gone the picture will be very clear
90% efficacy
Easy transport
Easy storage
Cheap price.
I think we have a winner here.
Can some one correct me ?
